ClinicalTrials.gg
CompletedNCT02266472Updated Mar 9, 2017Results posted

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

A Phase 1 interventional study of metformin and empagliflozin/metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and metformin extended release under fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects
  • age of 18 to 55 years
  • (BMI) of 18.5 to 29.9 kg/m2
  • additional inclusion criteria may apply

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg or diastolic blood pressure outside the range of 50 to 90 mmHg or pulse rate outside the range of 45 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication
  • Diseases of the central nervous system (including but not limited to any kind of seizures and stroke), and other relevant neurological disorders or psychiatric disorders
  • additional exclusion criteria may apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Fixed dose combination

    Single dose empagliflozin/metformin

    Drug: empagliflozin/metformin

  • Active comparator
    Single tablets combination

    single doses empagliflozin and metformin

    Drug: metformin · Drug: empagliflozin

Interventions

  • single dose of metformin given as tablets

  • Drugempagliflozin/metformin

    Drug pages: Empagliflozin · Metformin

    Single dose empagliflozin/metformin given as fixed-dose combination tablet

  • single dose of empagliflozin given as tablet

06

What researchers measure

Primary outcomes

  1. AUC0-tz of Empagliflozin in Plasma

    Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

  2. AUC0-tz of Metformin in Plasma

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

  3. Cmax of Empagliflozin in Plasma

    Maximum measured concentration of the empagliflozin in plasma

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

  4. Cmax of Metformin in Plasma

    Maximum measured concentration of the metformin in plasma

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

Secondary outcomes

  1. AUC0-infinity of Empagliflozin in Plasma

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

  2. AUC0-infinity of Metformin in Plasma

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration

07

Results

Posted Mar 9, 2017

Participant flow

Period 1+ Washout
Participant flow — Period 1+ Washout
MilestoneFed 10mg+1000mg Fixed Dose Combination (FDC)/Single (TR)Fed 10mg+1000mg Single/FDC (RT)
Started1515
Completed1515
Not completed00
Period 2+ Washout
Participant flow — Period 2+ Washout
MilestoneFed 10mg+1000mg Fixed Dose Combination (FDC)/Single (TR)Fed 10mg+1000mg Single/FDC (RT)
Started1515
Completed1515
Not completed00

Outcome measures

PrimaryAUC0-tz of Empagliflozin in Plasma

Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-tz of Empagliflozin in Plasma
nmol*h/LFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
AUC0-tz of Empagliflozin in Plasma2190 ± 18.12210 ± 16.3
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · p = <0.0001 · Ratio of the adjusted means: 99.11 · 90% CI 96.40 to 101.89Relative bioavailability of empagliflozin was estimated by the adjusted gMean ratio of Fed 10mg+1000mg FDC divided by Fed 10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).
PrimaryAUC0-tz of Metformin in Plasma

Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC0-tz of Metformin in Plasma
ng*h/mLFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
AUC0-tz of Metformin in Plasma10800 ± 20.110700 ± 22.4
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · p = <0.0001 · Ratio of the adjusted means: 101.25 · 90% CI 96.54 to 106.19Relative bioavailability of metformin was estimated by the adjusted gMean ratio of Fed 10mg+1000mg FDC divided by Fed 10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).
PrimaryCmax of Empagliflozin in Plasma

Maximum measured concentration of the empagliflozin in plasma

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · nmol/L
Cmax of Empagliflozin in Plasma
nmol/LFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
Cmax of Empagliflozin in Plasma243 ± 23.1245 ± 20.4
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · p = <0.0001 · Ratio of the adjusted means: 99.12 · 90% CI 93.69 to 104.87Relative bioavailability of empagliflozin was estimated by the adjusted gMean ratio of Fed10mg+1000mg FDC divided by Fed10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).
PrimaryCmax of Metformin in Plasma

Maximum measured concentration of the metformin in plasma

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax of Metformin in Plasma
ng/mLFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
Cmax of Metformin in Plasma1170 ± 25.51080 ± 25.2
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · p = <0.0001 · Ratio of the adjusted means: 108.58 · 90% CI 104.17 to 113.17Relative bioavailability of metformin was estimated by the adjusted gMean ratio of Fed10mg+1000mg FDC divided by Fed10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).
SecondaryAUC0-infinity of Empagliflozin in Plasma

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity of Empagliflozin in Plasma
nmol*h/LFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
AUC0-infinity of Empagliflozin in Plasma2230 ± 18.02260 ± 16.3
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · Ratio of the adjusted means: 98.89 · 90% CI 96.18 to 101.67Relative bioavailability of empagliflozin was estimated by the adjusted gMean ratio of Fed10mg+1000mg FDC divided by Fed10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).
SecondaryAUC0-infinity of Metformin in Plasma

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
-1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC0-infinity of Metformin in Plasma
ng*h/mLFed 10mg+ 1000mg FDC (T)Fed 10mg+1000mg Single (R)
AUC0-infinity of Metformin in Plasma11000 ± 20.810800 ± 22.7
Statistical analysis
  • Fed 10mg+ 1000mg FDC (T) vs Fed 10mg+1000mg Single (R) · ANOVA · Ratio of the adjusted means: 101.37 · 90% CI 96.53 to 106.45Relative bioavailability of metformin was estimated by the adjusted gMean ratio of Fed10mg+1000mg FDC divided by Fed10mg+1000mg Single. Standard deviation is actually intraindividual geometric coefficient variation (gCV).

Adverse events

Collected over From first drug administration until the end-of-trial examination (Up to 14 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fed 10mg+1000mg Single (R)—0/30 (0%)9/30 (30%)
Fed 10mg+ 1000mg FDC (T)—0/30 (0%)5/30 (16.7%)
Most frequent other events
Most frequent other events
EventFed 10mg+1000mg Single (R)Fed 10mg+ 1000mg FDC (T)
HeadacheNervous system disorders5/304/30
DiarrhoeaGastrointestinal disorders2/301/30
NauseaGastrointestinal disorders2/300/30

Baseline characteristics

Treated set (TS): The TS was made up of all randomised subjects who were documented to have received the trial medication.

Age, Continuous
Age, Continuous(years)Fed 10mg+1000mg FDC/Single (TR)Fed 10mg+1000mg Single/FDC (RT)Total
Mean33.5 ± 8.133.7 ± 10.133.6 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Fed 10mg+1000mg FDC/Single (TR)Fed 10mg+1000mg Single/FDC (RT)Total
Female6814
Male9716
08

Study locations

1 site
  • Boehringer Ingelheim Investigational Site
    Ingelheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2014
First posted
Oct 17, 2014
Start
Nov 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Mar 9, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02266472
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Nov 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Mar 9, 2017
Last update
Mar 9, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion